A5085590053- Melanoma and MAPK Pathways
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Immunotherapy and Immune Responses
- Protein Tyrosine Phosphatases
- Pancreatic and Hepatic Oncology Research
- Synthesis and biological activity
- PI3K/AKT/mTOR signaling in cancer
- Shoulder Injury and Treatment
- Computational Drug Discovery Methods
- Protein Degradation and Inhibitors
- Nutrition and Health Studies
- Radiopharmaceutical Chemistry and Applications
- Click Chemistry and Applications
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Prostate Cancer Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Synthesis of Tetrazole Derivatives
- Cancer Research and Treatments
- Renal cell carcinoma treatment
- Immune cells in cancer
Holy Cross University
2018-2023
Centrum Onkologii
2019-2021
Jagiellonian University
2020
Despite considerable progress made in the treatment of patients with advanced melanoma, majority treated BRAF and mitogen-activated protein inhibitors (BRAFi MEKi) experience a disease progression due to acquired resistance. Currently, ongoing studies explore possibility overcome or reverse this process. Our multicenter retrospective analysis included 51 metastatic -mutated melanoma who had previously progressed on BRAFi/MEKi than immunotherapy (anti-progression disease-1 anti-cytotoxic...
The landscape of melanoma management changed as randomized trials have launched adjuvant treatment.An analysis data on 248 consecutive stage III and IV patients given therapy in eight centers (February 2019 to January 2021) was conducted.The analyzed cohort comprised 147 anti-PD1 (33% nivolumab, 26% pembrolizumab), 101 (41%) were dabrafenib plus trametinib (DT). 2-year overall survival (OS), relapse-free (RFS), distant-metastases-free (DMFS) rates 86.7%, 61.4%, 70.2%, respectively. disease...
Pembrolizumab and nivolumab (anty-PD-1 antibody) are commonly used for the treatment of melanoma patients. However, their efficacy safety have never been directly compared, leaving little guidance clinicians to select best therapy. The study included patients with inoperable or metastatic treated in first line anti-PD-1 immunotherapy (nivolumab pembrolizumab). In total 1037 were enrolled study, 455 (44%) pembrolizumab 582 (56%) nivolumab. estimated median overall survival (OS) groups was...
Currently, limited data on targeted therapy and immunotherapy sequencing in patients with BRAF-mutant melanoma is available. Targeted are expected to be comparable terms of overall survival (OS) when used as second-line therapies; therefore, understanding the characteristics who completed sequential treatment needed. The primary objective this study was analyze efficacy BRAFi/MEKi activity advanced melanoma. We also aimed describe clinical were treated sequentially therapy. enrolled 97...
Neutrophil-to-lymphocyte ratio (NLR) has been shown to be prognostic in several solid malignancies. There are limited data regarding its value during novel therapies patients with melanoma. The aim of the study was assess practical utility this BRAF-mutant melanoma treated a combination BRAF and MEK inhibitors (BRAFi/MEKi). We included 215 inoperable or metastatic who underwent BRAFi/MEKi treatment between October 2015 June 2017. Baseline NLR other complete blood count-derived inflammatory...
Combined treatment with BRAFi and/or MEK inhibitors (MEKi) improves outcomes in advanced melanoma patients comparison monotherapy.We aim to report real-world efficacy and safety of vemurafenib (V) + cobimetinib (V C) from 10 years practice.A total 275 consecutive unresectable or metastatic BRAF mutated started first-line V C between 1 October 2013 31 December 2020. Survival analyses were performed using the Kaplan-Meier method, Log-rank Chi-square tests used for groups.The estimated median...
The relationship between immune related adverse events (irAEs) and efficacy is not definitively proven, data on the irAE treatment are contradictory.Five hundred ninety-three consecutive patients with unresectable or metastatic melanoma treated in first line anti-PD-1 (nivolumab pembrolizumab) January 2016 December 2019 were enrolled study.Statistically significant differences demonstrated group of without median OS PFS (p < .0001 both) also within 3, 6, 9 months from start therapy = .0121,...
(1) Background: BRAFi/MEKi are usually offered as a first line treatment for patients requiring rapid response; with elevated lactate dehydrogenase (LDH) activity, large tumor burden, and brain metastases. The efficacy of second therapies after BRAFi/MEKI failure is now well defined. (2) Methods: Patients treated target therapy (vemurafenib plus cobimetinib, dabrafenib trametinib or encorafenib binimetinib); the immunotherapy programmed cell death 1 (PD-1) checkpoint inhibitors (nivolumab...
e21514 Background: Anti-programmed cell death-1 antibodies (anti-PD-1) have become a standard treatment option for melanoma patients. Currently, two anti-PD-1 are registered in the of patients: nivolumab and pembrolizumab. Nivolumab is human monoclonal antibody, while pembrolizumab humanized antibody. Unfortunately, there very few clinical data comparing efficacy toxicity routine practice. Methods: Consecutive patients treated first line with (nivolumab or pembrolizumab) unresectable...
e21550 Background: First line BRAFi/MEKi therapy in metastatic melanoma eventually result drug resistance and disease progression. Because develops at least partially by epigenetic mechanisms, it may potentially be reversed after discontinuation. Therefore we aim to explore the clinical efficacy of rechallenge 3 treatment. Moreover reports on immunotherapy were contradictory, so enrolled patients treated sequentially this scenario. Methods: In country-wide multicenter retrospective analysis...
Anti-EGFR antibodies combined with chemotherapy doublets are a cornerstone of the upfront treatment colorectal cancer. RAS and BRAF mutations established negative predictive factors for such therapy. The primary tumour located in proximal colon has recently emerged as another factor. We have conducted retrospective multicentre study to collect data on real-world population characteristics, practice patterns, outcomes patients metastatic cancer treated first-line setting either cetuximab or...
e21539 Background: The use of targeted therapies (TT) and checkpoint inhibitors (IT) significantly prolonged survival in patients with metastatic melanoma, especially BRAF mutation-positive melanoma. Optimal sequence is still a matter debate. aim this study was to evaluate real-life practice outcomes melanoma treated sequentially. Methods: Consecutive unresectable or started treatment TT (BRAF MEK inhibitors) and/or IT (anti-PD1) between 1/Oct/2016 31/Dec/2020. Clinical factors including...
e21552 Background: Nivolumab plus ipilimumab (NIVO+IPI), a first-in-class combination immunotherapy, has dramatically changed the treatment paradigm for melanoma in recent years. The aim of this study was to analyze patterns, response, survival, safety, and healthcare resource utilization with first-line therapy patients (pts) advanced under real-world conditions. Methods: This retrospective analysis included pts stage 3 unresectable 4 treated 01/2021-06/2022 NIVO+IPI at 6 centers Poland...
The treatment of patients with prostate cancer, who do not qualify for the radical therapy is based on use surgical or pharmacological castration methods. effectiveness so-called androgen deprivation tends to decrease over time. Even in absence distant metastases imaging studies, resistance hormonal may be developed. At this moment, new generation receptor inhibitors reduce risk death. paper presents a case report patient cancer without started apalutamide at moment developing re-sistance castration.
Introduction: Sciatica (Ischias) is a set of symptoms associated with the compression L4, L5 and S1 spinal nerves, forming sciatic nerve, largest peripheral human nerve. Pain can radiate to buttock, lateral surface hip, calf foot. The individual risk factors for sciatica include height, body mass, muscle strength, physical condition. I n d i v u l f c t o r s e pregnancies births. aim this study was assess compare level activity fitness people treated results tests carried out among healthy...
ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Dziura R, Macek P, Smok-Kalwat J, Góźdź S. Radical therapy of resectable and borderline pancreatic cancer – present state knowledge. Do we have sufficient data to use neoadjuvant treatment?. Medical Studies/Studia Medyczne. 2020;36(2):142-147. doi:10.5114/ms.2020.96795. APA Dziura, R., Macek, P., Smok-Kalwat, J., & Góźdź, (2020). Medyczne, 36(2), 142-147. https://doi.org/10.5114/ms.2020.96795 Chicago Robert,...
e21544 Background: BRAF-mutated (MUT) melanoma is characterized by specific clinical features including more aggressive biological behavior than BRAF wild-type (WT) melanoma. mutations are historically known as negative prognostic factor for to shorter overall survival (OS) in patients with stage IV disease Methods: Consecutive unresectable or metastatic started treatment inhibitors (BRAFi), BRAFi and MEK (MEKi) IT (anti-PD-1 antibody) between 1/Jan/2013 31/Dec/2020. Clinical factors age,...